Aug 4, 2010
A letter from Vice President for Research and Dean of the Graduate College Rathindra Bose to the University community:
Thanks to the talent and ingenuity of Ohio University faculty, the institution reached several important milestones in fiscal year 2010:
The University System of Ohio recognized Ohio University’s research in the areas of “energy and the environment” and “health and wellness” as state “Centers of Excellence.” A third proposal for the Scripps College of Communication is pending approval. These centers encompass research and scholarship programs that already have made an impact on the state, national, and international stage, and have strong potential for growth.
Although we are still compiling data on total research and sponsored program awards for last year, I’m pleased to announce that early reports show that our federal funding for research has increased.
Ohio University also reported $8.2 million in income from its research technologies in fiscal year 2010, the majority of which came from licenses for health and medical advances for growth hormone and thyroid disorders.
The university received more than $8 million from the Pfizer corporation from a license for a growth hormone antagonist that became the basis for the drug Somavert. The drug is used for patients with acromegaly, a form of gigantism that affects 40,000 people worldwide.
Ohio University also receives income from its license to Diagnostic Hybrids, Inc., (a Quidel company) and Interthyr for a research discovery that led to the development of Thyretain, a new test for detecting the thyroid disorder Graves’ disease in patients.
The Innovation Center, which continues to help faculty turn research discoveries into start-up companies, now boasts 17 tenants striving to enhance our regional economy. These clients include EZ Asphalt, Inc., founded by Associate Professor of Civil Engineering Sang-Soo Kim to develop a technology that can determine when road pavements will crack. Interthyr, based on the research of Emeritus Professor Leonard Kohn, is developing a compound that may help treat certain cancers and autoimmune disorders.
Ohio University also is making strides in graduate education. The Graduate College, an initiative of the university’s strategic planning process, is now firmly established. I’m pleased to report that we graduated 1,000 master’s students and 160 doctoral students in June. Over the past decade, the number of students earning a Ph.D. from Ohio University has steadily increased.